Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 10/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.50 |
| ▸ | IP6K1 | Q92551 | 5/20 | 0.49 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.49 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.49 |
| ▸ | PIM1 | P11309 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | AKT1 | P31749 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.49 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12332880 | 0.92 | PARP1 (0.46) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL12304877 | 0.88 | PARP1 (0.53) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL12788028 | 0.88 | PARP1 (0.53) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL12788049 | 0.87 | PARP1 (0.51) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL12304872 | 0.87 | PARP1 (0.51) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL256397 | 0.81 | ROCK2 (0.50) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL22980875 | 0.76 | IP6K1 (0.66) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL4066634 | 0.76 | PARP1 (0.58) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL164053 | 0.76 | PARP1 (0.62) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL13395634 | 0.75 | IP6K1 (0.54) | PARP1PDPK1CA12ALOX15SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735410-B2 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2014-05-27 | — | — | US | disclosed |
| US-8399667-B2 | 4-anilino quinazoline derivatives as antiproliferative agents | ASTRAZENECA AB (GB) | 2013-03-19 | — | — | US | disclosed |
| US-20130005727-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2013-01-03 | — | — | US | disclosed |
| US-20130005727-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2013-01-03 | — | — | US | disclosed |
| US-20120329795-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB | 2012-12-27 | — | — | US | disclosed |
| US-20120329795-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB | 2012-12-27 | — | — | US | disclosed |
| US-8318752-B2 | antiproliferative agent in the prevention or treatment of tumors which are sensitive to inhibition of EGF and erbB receptor tyrosine kinases | ASTRAZENECA AB (SE) | 2012-11-27 | — | — | US | disclosed |
| US-20110237610-A1 | Quinazoline Derivatives as Antiproliferative Agents | ASTRAZENECA AB (SE) | 2011-09-29 | — | — | US | disclosed |
| US-20110237610-A1 | Quinazoline Derivatives as Antiproliferative Agents | ASTRAZENECA AB (SE) | 2011-09-29 | — | — | US | disclosed |
| US-20110152297-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | Astra Zeneca AB Corporation | 2011-06-23 | — | — | US | disclosed |
| US-20110152297-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | Astra Zeneca AB Corporation | 2011-06-23 | — | — | US | disclosed |
| US-7838530-B2 | Quinazoline derivatives as antiproliferative agents | ASTRAZENECA AB (SE) | 2010-11-23 | — | — | US | disclosed |
| EP-1487806-B1 | 4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | ASTRAZENECA AB (SE) | 2010-07-07 | — | — | EP | disclosed |
| US-20100152442-A1 | 4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | ASTRAZENECA AB | 2010-06-17 | — | — | US | disclosed |
| US-7632840-B2 | Quinazoline compounds for the treatment of hyperproliferative disorders | ASTRAZENECA AB (SE) | 2009-12-15 | — | — | US | disclosed |
| US-20080269487-A1 | 4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | ASTRAZENECA AB | 2008-10-30 | — | — | US | disclosed |
| US-20080234263-A1 | Quinazoline Derivatives | ASTRAZENECA (SE) | 2008-09-25 | — | — | US | disclosed |
| US-20080096881-A1 | Quinazoline Derivatives | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| US-20070293490-A1 | Quinazoline Derivatives | ASTRAZENECA AB (SE) | 2007-12-20 | — | — | US | disclosed |
| US-20070037837-A1 | Antiproliferative agent in the prevention or treatment of tumors which are sensitive to inhibition of EGF and erbB receptor tyrosine kinases;1-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}methyl)-L-prolinamide | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005727-A1 | QUINAZOLINE DERIVATIVES | ABL1, ERBB2, EGFR | PARP1 873/4885PDPK1 217/4885CA12 3490/4885 |
| US-20080234263-A1 | Quinazoline Derivatives | EGFR, ERBB2, ERBB3 | PARP1 1220/4885PDPK1 473/4885CA12 3382/4885 |
| US-20110237610-A1 | Quinazoline Derivatives as Antiproliferative Agents | ERBB2, EGFR, MKI67 | PARP1 774/4885PDPK1 308/4885CA12 4118/4885 |
| US-20080269487-A1 | 4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | ERBB2, ERBB4, EGFR | PARP1 787/4885PDPK1 214/4885CA12 4228/4885 |
| US-20120329795-A1 | QUINAZOLINE DERIVATIVES | EGFR, ERBB2, ERBB3 | PARP1 1778/4885PDPK1 760/4885CA12 4085/4885 |
| US-20100152442-A1 | 4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | ERBB2, ERBB4, EGFR | PARP1 787/4885PDPK1 214/4885CA12 4228/4885 |
| US-20070293490-A1 | Quinazoline Derivatives | CCNA1, CCND3, CCND2 | PARP1 186/4885PDPK1 870/4885CA12 4806/4885 |
| US-20110152297-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ERBB2, ABL1, EGFR | PARP1 1997/4885PDPK1 305/4885CA12 4555/4885 |
| US-20070037837-A1 | Antiproliferative agent in the prevention or treatment of tumors which are sensitive to inhibition of EGF and erbB receptor tyrosine kinases;1-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}methyl)-L-prolinamide | EGFR, ERBB2, ERBB3 | PARP1 1668/4885PDPK1 451/4885CA12 4305/4885 |
| US-20080096881-A1 | Quinazoline Derivatives | EGFR, ERBB2, ERBB3 | PARP1 1586/4885PDPK1 674/4885CA12 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.